American Psychiatric Association (2000). „Schizophrenia”. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Publishing, Inc.. ISBN0-89042-024-6. Pristupljeno 2008-07-04.
Becker T, Kilian R (2006). „Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?”. Acta Psychiatrica Scandinavica Supplement113 (429): 9–16. DOI:10.1111/j.1600-0447.2005.00711.x. ISSN0001-690X. PMID16445476.
O'Donovan MC, Williams NM, Owen MJ (October 2003). „Recent advances in the genetics of schizophrenia”. Hum. Mol. Genet.12 Spec No 2: R125–33. DOI:10.1093/hmg/ddg302. PMID12952866.
McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W (January 2010). „Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies”. Int. J. Drug Policy21 (1): 10–9. DOI:10.1016/j.drugpo.2009.09.001. PMID19783132.
O'Donovan MC, Craddock NJ, Owen MJ (July 2009). „Genetics of psychosis; insights from views across the genome”. Hum. Genet.126 (1): 3–12. DOI:10.1007/s00439-009-0703-0. PMID19521722.
Crow TJ (July 2008). „The 'big bang' theory of the origin of psychosis and the faculty of language”. Schizophrenia Research102 (1–3): 31–52. DOI:10.1016/j.schres.2008.03.010. PMID18502103.
Jim van Os (2004). „Does the urban environment cause psychosis?”. British Journal of Psychiatry184 (4): 287–288. DOI:10.1192/bjp.184.4.287. PMID15056569.
Selten JP, Cantor-Graae E, Kahn RS (March 2007). „Migration and schizophrenia”. Current Opinion in Psychiatry20 (2): 111–115. DOI:10.1097/YCO.0b013e328017f68e. PMID17278906.
Large M, Sharma S, Compton MT, Slade T, Nielssen O (June 2011). „Cannabis use and earlier onset of psychosis: a systematic meta-analysis”. Arch. Gen. Psychiatry68 (6): 555–61. DOI:10.1001/archgenpsychiatry.2011.5. PMID21300939.
Moore THM, Zammit S, Lingford-Hughes A et al.. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–328. doi:10.1016/S0140-6736(07)61162-3. PMID17662880.
Sewell, RA; Ranganathan, M, D'Souza, DC (2009). „Cannabinoids and psychosis”. International review of psychiatry (Abingdon, England)21 (2): 152–62. DOI:10.1080/09540260902782802. PMID19367509.
Bentall RP, Fernyhough C, Morrison AP, Lewis S, Corcoran R. Prospects for a cognitive-developmental account of psychotic experiences. Br J Clin Psychol. 2007;46(Pt 2):155–73. doi:10.1348/014466506X123011. PMID17524210.
Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophrenia Research. 2005;74(1):15–26. doi:10.1016/j.schres.2004.07.005. PMID15694750.
Cohen AS, Docherty NM. Affective reactivity of speech and emotional experience in patients with schizophrenia. Schizophrenia Research. 2004;69(1):7–14. doi:10.1016/S0920-9964(03)00069-0. PMID15145465.
Horan WP, Blanchard JJ. Emotional responses to psychosocial stress in schizophrenia: the role of individual differences in affective traits and coping. Schizophrenia Research. 2003;60(2–3):271–83. doi:10.1016/S0920-9964(02)00227-X. PMID12591589.
Smith B, Fowler DG, Freeman D,et al.. Emotion and psychosis: links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations. Schizophr. Res.. 2006;86(1–3):181–8. doi:10.1016/j.schres.2006.06.018. PMID16857346.
Beck, AT. A Cognitive Model of Schizophrenia. Journal of Cognitive Psychotherapy. 2004;18(3):281–88. doi:10.1891/jcop.18.3.281.65649.
Bell V, Halligan PW, Ellis HD. Explaining delusions: a cognitive perspective. Trends in Cognitive Science. 2006;10(5):219–26. doi:10.1016/j.tics.2006.03.004. PMID16600666.
Freeman D, Garety PA, Kuipers E, Fowler D, Bebbington PE, Dunn G. Acting on persecutory delusions: the importance of safety seeking. Behav Res Ther. 2007;45(1):89–99. doi:10.1016/j.brat.2006.01.014. PMID16530161.
Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. British Journal of Psychiatry. 2002;181:271–275. doi:10.1192/bjp.181.4.271. PMID12356650.
Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacology and Therapeutics. 2003;97(2):153–79. doi:10.1016/S0163-7258(02)00328-5. PMID12559388.
Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25(4):455–67. doi:10.1016/S0893-133X(01)00243-3. PMID11557159.
Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Annals of the New York Academy of Sciences. 2003;1003:318–27. doi:10.1196/annals.1300.020. PMID14684455.
Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research. 2005;72(2–3):225–34. doi:10.1016/j.schres.2004.05.005. PMID15560967.
Jakobsen KD, Frederiksen JN, Hansen T, et al.. Reliability of clinical ICD-10 schizophrenia diagnoses. Nordic Journal of Psychiatry. 2005;59(3):209–12. doi:10.1080/08039480510027698. PMID16195122.
de Koning MB, Bloemen OJ, van Amelsvoort TA, et al.. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr Scand. 2009;119(6):426–42. doi:10.1111/j.1600-0447.2009.01372.x. PMID19392813.
Arendt, M; Rosenberg, R, Foldager, L, Perto, G, Munk-Jørgensen, P (2005). „Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases”. The British journal of psychiatry : the journal of mental science187 (6): 510–5. DOI:10.1192/bjp.187.6.510. PMID16319402.
Leucht, Stefan; Tardy, Magdolna, Komossa, Katja, Heres, Stephan, Kissling, Werner, Salanti, Georgia, Davis, John M (2012-05-01). „Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis”. The Lancet. DOI:10.1016/S0140-6736(12)60239-6.
Wahlbeck K, Cheine MV, Essali A. Clozapine versus typical neuroleptic medication for schizophrenia. The Cochrane Database of Systematic Reviews. 2007;(2):CD000059. doi:10.1002/14651858.CD000059. PMID10796289.
Tandon R, Belmaker RH, Gattaz WF, et al.. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res.. 2008;100(1–3):20–38. doi:10.1016/j.schres.2007.11.033. PMID18243663.
Dixon LB, Dickerson F, Bellack AS, et al.. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):48–70. doi:10.1093/schbul/sbp115. PMID19955389.
Lynch D, Laws KR, McKenna PJ. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol Med. 2010;40(1):9–24. doi:10.1017/S003329170900590X. PMID19476688.
Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev. 2004;(4):CD000524. doi:10.1002/14651858.CD000524.pub2. PMID15495000.
Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry. 2007;64(10):1123–31. doi:10.1001/archpsyc.64.10.1123. PMID17909124.
Ustun TB; Rehm J, Chatterji S, Saxena S, Trotter R, Room R, Bickenbach J, and the WHO/NIH Joint Project CAR Study Group (1999). „Multiple-informant ranking of the disabling effects of different health conditions in 14 countries”. The Lancet354 (9173): 111–15. DOI:10.1016/S0140-6736(98)07507-2. PMID10408486.
Palmer BA, Pankratz VS, Bostwick JM (March 2005). „The lifetime risk of suicide in schizophrenia: a reexamination”. Archives of General Psychiatry62 (3): 247–53. DOI:10.1001/archpsyc.62.3.247. PMID15753237.
Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P. Suicide in schizophrenia. Expert Rev Neurother. 2010;10(7):1153–64. doi:10.1586/ern.10.82. PMID20586695.
De Leon J, Diaz FJ (2005). „A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors”. Schizophrenia research76 (2-3): 135–57. DOI:10.1016/j.schres.2005.02.010. PMID15949648.
Castle D, Wessely S, Der G, Murray RM. The incidence of operationally defined schizophrenia in Camberwell, 1965–84. The British Journal of Psychiatry. 1991;159:790–4. doi:10.1192/bjp.159.6.790. PMID1790446.
Jablensky A, Sartorius N, Ernberg G, et al. (1992). „Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study”. Psychological Medicine Monograph Supplement20: 1–97. DOI:10.1017/S0264180100000904. PMID1565705.
Kirkbride JB, Fearon P, Morgan C, et al. (March 2006). „Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study”. Archives of General Psychiatry63 (3): 250–8. DOI:10.1001/archpsyc.63.3.250. PMID16520429.
Kirkbride JB, Fearon P, Morgan C, et al. (2007). „Neighbourhood variation in the incidence of psychotic disorders in Southeast London”. Social Psychiatry and Psychiatric Epidemiology42 (6): 438–45. DOI:10.1007/s00127-007-0193-0. PMID17473901.
Heinrichs RW. Historical origins of schizophrenia: two early madmen and their illness. Journal of the History of the Behavioral Sciences. 2003;39(4):349–63. doi:10.1002/jhbs.10152. PMID14601041.
Large, M; Smith, G, Nielssen, O (2009). „The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis”. Schizophrenia research112 (1–3): 123–9. DOI:10.1016/j.schres.2009.04.004. PMID19457644.
Phelan JC, Link BG, Stueve A, Pescosolido BA. Public Conceptions of Mental Illness in 1950 and 1996: What Is Mental Illness and Is It to be Feared?. Journal of Health and Social Behavior. 2000;41(2):188–207. doi:10.2307/2676305.
Moore THM, Zammit S, Lingford-Hughes A et al.. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–328. doi:10.1016/S0140-6736(07)61162-3. PMID17662880.
Bentall RP, Fernyhough C, Morrison AP, Lewis S, Corcoran R. Prospects for a cognitive-developmental account of psychotic experiences. Br J Clin Psychol. 2007;46(Pt 2):155–73. doi:10.1348/014466506X123011. PMID17524210.
Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophrenia Research. 2005;74(1):15–26. doi:10.1016/j.schres.2004.07.005. PMID15694750.
Cohen AS, Docherty NM. Affective reactivity of speech and emotional experience in patients with schizophrenia. Schizophrenia Research. 2004;69(1):7–14. doi:10.1016/S0920-9964(03)00069-0. PMID15145465.
Horan WP, Blanchard JJ. Emotional responses to psychosocial stress in schizophrenia: the role of individual differences in affective traits and coping. Schizophrenia Research. 2003;60(2–3):271–83. doi:10.1016/S0920-9964(02)00227-X. PMID12591589.
Smith B, Fowler DG, Freeman D,et al.. Emotion and psychosis: links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations. Schizophr. Res.. 2006;86(1–3):181–8. doi:10.1016/j.schres.2006.06.018. PMID16857346.
Bell V, Halligan PW, Ellis HD. Explaining delusions: a cognitive perspective. Trends in Cognitive Science. 2006;10(5):219–26. doi:10.1016/j.tics.2006.03.004. PMID16600666.
Freeman D, Garety PA, Kuipers E, Fowler D, Bebbington PE, Dunn G. Acting on persecutory delusions: the importance of safety seeking. Behav Res Ther. 2007;45(1):89–99. doi:10.1016/j.brat.2006.01.014. PMID16530161.
Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. Journal of Clinical Psychiatry. 2006;67(Suppl 9):3–8. PMID16965182.
Jones HM, Pilowsky LS. Dopamine and antipsychotic drug action revisited. British Journal of Psychiatry. 2002;181:271–275. doi:10.1192/bjp.181.4.271. PMID12356650.
Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacology and Therapeutics. 2003;97(2):153–79. doi:10.1016/S0163-7258(02)00328-5. PMID12559388.
Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25(4):455–67. doi:10.1016/S0893-133X(01)00243-3. PMID11557159.
Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Annals of the New York Academy of Sciences. 2003;1003:318–27. doi:10.1196/annals.1300.020. PMID14684455.
Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research. 2005;72(2–3):225–34. doi:10.1016/j.schres.2004.05.005. PMID15560967.
Jakobsen KD, Frederiksen JN, Hansen T, et al.. Reliability of clinical ICD-10 schizophrenia diagnoses. Nordic Journal of Psychiatry. 2005;59(3):209–12. doi:10.1080/08039480510027698. PMID16195122.
McGlashan TH. Testing DSM-III symptom criteria for schizotypal and borderline personality disorders. Archives of General Psychiatry. 1987;44(2):143–8. PMID3813809.
de Koning MB, Bloemen OJ, van Amelsvoort TA, et al.. Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr Scand. 2009;119(6):426–42. doi:10.1111/j.1600-0447.2009.01372.x. PMID19392813.
Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345–57. PMID20954430.
Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75(12):1821–9. PMID17619525.
Wahlbeck K, Cheine MV, Essali A. Clozapine versus typical neuroleptic medication for schizophrenia. The Cochrane Database of Systematic Reviews. 2007;(2):CD000059. doi:10.1002/14651858.CD000059. PMID10796289.
Tandon R, Belmaker RH, Gattaz WF, et al.. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res.. 2008;100(1–3):20–38. doi:10.1016/j.schres.2007.11.033. PMID18243663.
Dixon LB, Dickerson F, Bellack AS, et al.. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):48–70. doi:10.1093/schbul/sbp115. PMID19955389.
Lynch D, Laws KR, McKenna PJ. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials. Psychol Med. 2010;40(1):9–24. doi:10.1017/S003329170900590X. PMID19476688.
Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. Cochrane Database Syst Rev. 2004;(4):CD000524. doi:10.1002/14651858.CD000524.pub2. PMID15495000.
Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry. 2007;64(10):1123–31. doi:10.1001/archpsyc.64.10.1123. PMID17909124.
Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P. Suicide in schizophrenia. Expert Rev Neurother. 2010;10(7):1153–64. doi:10.1586/ern.10.82. PMID20586695.
Castle D, Wessely S, Der G, Murray RM. The incidence of operationally defined schizophrenia in Camberwell, 1965–84. The British Journal of Psychiatry. 1991;159:790–4. doi:10.1192/bjp.159.6.790. PMID1790446.
Heinrichs RW. Historical origins of schizophrenia: two early madmen and their illness. Journal of the History of the Behavioral Sciences. 2003;39(4):349–63. doi:10.1002/jhbs.10152. PMID14601041.
Wilson M. DSM-III and the transformation of American psychiatry: a history. American Journal of Psychiatry. 1993;150(3):399–410. PMID8434655.
Kim Y, Berrios GE. Impact of the term schizophrenia on the culture of ideograph: the Japanese experience. Schizophr Bull. 2001;27(2):181–5. PMID11354585.
Becker T, Kilian R (2006). „Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?”. Acta Psychiatrica Scandinavica Supplement113 (429): 9–16. DOI:10.1111/j.1600-0447.2005.00711.x. ISSN0001-690X. PMID16445476.
O'Donovan MC, Williams NM, Owen MJ (October 2003). „Recent advances in the genetics of schizophrenia”. Hum. Mol. Genet.12 Spec No 2: R125–33. DOI:10.1093/hmg/ddg302. PMID12952866.
McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W (January 2010). „Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies”. Int. J. Drug Policy21 (1): 10–9. DOI:10.1016/j.drugpo.2009.09.001. PMID19783132.
O'Donovan MC, Craddock NJ, Owen MJ (July 2009). „Genetics of psychosis; insights from views across the genome”. Hum. Genet.126 (1): 3–12. DOI:10.1007/s00439-009-0703-0. PMID19521722.
Crow TJ (July 2008). „The 'big bang' theory of the origin of psychosis and the faculty of language”. Schizophrenia Research102 (1–3): 31–52. DOI:10.1016/j.schres.2008.03.010. PMID18502103.
Jim van Os (2004). „Does the urban environment cause psychosis?”. British Journal of Psychiatry184 (4): 287–288. DOI:10.1192/bjp.184.4.287. PMID15056569.
Selten JP, Cantor-Graae E, Kahn RS (March 2007). „Migration and schizophrenia”. Current Opinion in Psychiatry20 (2): 111–115. DOI:10.1097/YCO.0b013e328017f68e. PMID17278906.
Large M, Sharma S, Compton MT, Slade T, Nielssen O (June 2011). „Cannabis use and earlier onset of psychosis: a systematic meta-analysis”. Arch. Gen. Psychiatry68 (6): 555–61. DOI:10.1001/archgenpsychiatry.2011.5. PMID21300939.
Sewell, RA; Ranganathan, M, D'Souza, DC (2009). „Cannabinoids and psychosis”. International review of psychiatry (Abingdon, England)21 (2): 152–62. DOI:10.1080/09540260902782802. PMID19367509.
Sagud, M; Mihaljević-Peles, A, Mück-Seler, D, Pivac, N, Vuksan-Cusa, B, Brataljenović, T, Jakovljević, M (2009). „Smoking and schizophrenia”. Psychiatria Danubina21 (3): 371–5. PMID19794359.
Arendt, M; Rosenberg, R, Foldager, L, Perto, G, Munk-Jørgensen, P (2005). „Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases”. The British journal of psychiatry : the journal of mental science187 (6): 510–5. DOI:10.1192/bjp.187.6.510. PMID16319402.
Ustun TB; Rehm J, Chatterji S, Saxena S, Trotter R, Room R, Bickenbach J, and the WHO/NIH Joint Project CAR Study Group (1999). „Multiple-informant ranking of the disabling effects of different health conditions in 14 countries”. The Lancet354 (9173): 111–15. DOI:10.1016/S0140-6736(98)07507-2. PMID10408486.
Isaac M, Chand P, Murthy P (August 2007). „Schizophrenia outcome measures in the wider international community”. Br J Psychiatry Suppl50: s71–7. PMID18019048.
Burns J (August 2009). „Dispelling a myth: developing world poverty, inequality, violence and social fragmentation are not good for outcome in schizophrenia”. Afr J Psychiatry (Johannesbg)12 (3): 200–5. PMID19894340.
Palmer BA, Pankratz VS, Bostwick JM (March 2005). „The lifetime risk of suicide in schizophrenia: a reexamination”. Archives of General Psychiatry62 (3): 247–53. DOI:10.1001/archpsyc.62.3.247. PMID15753237.
De Leon J, Diaz FJ (2005). „A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors”. Schizophrenia research76 (2-3): 135–57. DOI:10.1016/j.schres.2005.02.010. PMID15949648.
Jablensky A, Sartorius N, Ernberg G, et al. (1992). „Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study”. Psychological Medicine Monograph Supplement20: 1–97. DOI:10.1017/S0264180100000904. PMID1565705.
Kirkbride JB, Fearon P, Morgan C, et al. (March 2006). „Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study”. Archives of General Psychiatry63 (3): 250–8. DOI:10.1001/archpsyc.63.3.250. PMID16520429.
Kirkbride JB, Fearon P, Morgan C, et al. (2007). „Neighbourhood variation in the incidence of psychotic disorders in Southeast London”. Social Psychiatry and Psychiatric Epidemiology42 (6): 438–45. DOI:10.1007/s00127-007-0193-0. PMID17473901.
Large, M; Smith, G, Nielssen, O (2009). „The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis”. Schizophrenia research112 (1–3): 123–9. DOI:10.1016/j.schres.2009.04.004. PMID19457644.
„Schizophrenia”. World Health Organization. 2011. Pristupljeno 2011-02-27.
worldcat.org
Becker T, Kilian R (2006). „Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?”. Acta Psychiatrica Scandinavica Supplement113 (429): 9–16. DOI:10.1111/j.1600-0447.2005.00711.x. ISSN0001-690X. PMID16445476.